Celcuity Inc. has released a corporate presentation highlighting their progress in cancer treatment, focusing on the PI3K/AKT/mTOR pathway. The presentation details the efficacy of gedatolisib in treating HR+/HER2- advanced breast cancer. Notably, the gedatolisib triplet and doublet therapies demonstrated significant improvement in median progression-free survival compared to fulvestrant alone. The company is currently enrolling patients for a Phase 3 study in first-line HR+/HER2- advanced breast cancer and conducting a Phase 1b/2 trial in second-line metastatic castration-resistant prostate cancer. Celcuity emphasizes the potential of PAM pathway inhibitors in oncology, targeting a large patient population in the US, Europe, and Japan. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.